About Us
An independent, standardized rating for pharmaceutical reimbursement risk — built so a decision can be defended long after it is made.
Where We Started
MARA Rating Company was formally established in Switzerland in 2025, building on a reimbursement-prediction practice that dates to 2020. Its partners are former HTA reviewers, payer decision-makers, and investment-bank analysts.
We spent our careers on different sides of the same decision — assessing assets, setting reimbursement, and pricing transactions. From every seat, one pattern held: strong clinical results did not guarantee market access, and the distance between the two was rarely measured before capital was committed.
We answered it the way credit markets once answered default risk — with a disciplined, repeatable rating, built on direct experience across HTA bodies including NICE, ICER, and their EU4 counterparts, and across global payer systems.
Why MARA Rating Exists
Market access is one of the largest drivers of commercial success, and one of the least systematically measured. Internal forecasts tend to overestimate reimbursement outcomes, and without an external reference point, due diligence can harden into structured groupthink.
Regulatory approval clears the first gate. Reimbursement is the second — and it is where deal value and launch plans are most often lost.
MARA Rating® exists to make that second gate measurable. It gives decision-makers an independent benchmark that holds steady across assets, therapeutic areas, and market contexts — so that high-stakes calls rest on a defensible standard, not on internal confidence alone.
Our Principles
Independence
Free from advisory conflicts and post-sale dependencies — our ratings reflect evidence and structured judgment, not client advocacy.Evidence-Linked
All scores are grounded in public, verifiable evidence and calibrated to historical HTA and payer outcomes.Standardization Over Subjectivity
Scores are calibrated to historical HTA and payer outcomes and back-tested against real launches. The same asset yields the same rating, whoever applies it.
Before the next high-stakes decision, one question is worth asking: if it is challenged later, what independent benchmark did it rest on?
our independent asessments
How Organizations Use MARA Ratings
Organizations rely on MARA Ratings as an independent, standardized reference in decision situations where capital commitment, portfolio prioritization, or launch risk is evaluated against payer evidence.
Governance & Calibration
MARA Ratings are governed through a documented committee charter, defined rating actions, and periodic calibration against historical payer decisions. This ensures consistency, comparability, and defensibility over time.